Clinical Trial Update: A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD [Phase 1]

View source ↗

Summary

Phase 1 safety study of IV stem cell-derived extracellular vesicles (UNEX-42) in preterm neonates at high risk for bronchopulmonary dysplasia; study terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchopulmonary Dysplasia

Drugs mentioned

• UNEX-42

Snippet

Sponsor: United Therapeutics | Conditions: Bronchopulmonary Dysplasia | Phase 1 | Status: TERMINATED | Results posted: 2021-10-12